The cost of Orladeyo (berotralstat) can vary. In the United States, a 90-day supply of Orladeyo is typically priced around $148,500 [1]. This translates to a monthly cost of approximately $49,500 [1].
How is the price of Orladeyo determined?
Drug pricing in the United States is complex and influenced by several factors, including research and development costs, manufacturing expenses, marketing, and the perceived value the drug brings to patients. For Orladeyo, a targeted therapy for hereditary angioedema (HAE), the cost reflects its specialized nature and the limited patient population it serves [2]. The drug is a first-in-class oral kallikrein inhibitor, offering a new treatment option for individuals with HAE [3].
What financial assistance programs are available for Orladeyo?
For patients in the U.S. who meet certain eligibility requirements, financial assistance programs may be available to help offset the cost of Orladeyo. These programs can include co-pay assistance and patient support services designed to make treatment more accessible [1]. Information regarding these programs can often be found through the drug manufacturer or patient advocacy groups.
How does Orladeyo's cost compare to other HAE treatments?
Orladeyo's pricing positions it within the landscape of treatments for rare diseases, which often carry high price tags due to the complexity of development and smaller patient populations. Other HAE treatments, including intravenous and subcutaneous therapies, also represent significant financial investments [2]. The value proposition of Orladeyo lies in its oral administration and its mechanism of action as a preventative treatment [3].
When does Orladeyo's patent expire?
The patent protection for Orladeyo is a critical factor in its long-term market availability and potential future cost changes. Drug patent expiry dates can be tracked on specialized databases. Information on Orladeyo's patent status and expected expiry can be accessed through resources like DrugPatentWatch.com [4].
What is the mechanism of action for Orladeyo?
Orladeyo works by inhibiting plasma kallikrein. Kallikrein is an enzyme that plays a role in the inflammatory cascade that leads to HAE attacks. By blocking kallikrein, Orladeyo helps to reduce the frequency and severity of these attacks [3].
What are the clinical trial results for Orladeyo?
Clinical trials for Orladeyo have demonstrated its efficacy in reducing the number of HAE attacks. For instance, in the APeX-2 trial, patients treated with Orladeyo experienced a significant reduction in the monthly HAE attack rate compared to placebo [3].
What are the potential side effects of Orladeyo?
Common side effects reported in clinical trials for Orladeyo include gastrointestinal issues such as diarrhea, abdominal pain, and nausea. Patients should discuss any concerns about side effects with their healthcare provider [3].
Who manufactures Orladeyo?
Orladeyo is manufactured by BioCryst Pharmaceuticals [5].
What is hereditary angioedema (HAE)?
Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent episodes of severe swelling, known as angioedema, which can affect various parts of the body, including the face, limbs, abdomen, and airway [2]. These attacks can be painful and potentially life-threatening if they affect the airway [3].
---
1. https://www.drugpatentwatch.com/drug/orladeyo
2. https://www.biocryst.com/patients/orladeyo/
3. https://www.rxlist.com/orladeyo-drug-frequently-asked-questions/patient-guide.htm
4. https://www.drugpatentwatch.com/
5. https://www.biocryst.com/